Cognito Therapeutics and Rhode Island Life Science Hub Launch Brain Health Collaboratory
Summary
Cognito Therapeutics, the Cambridge, Massachusetts neuromodulation company behind the Spectris platform, has partnered with the Rhode Island Life Science Hub to launch the Rhode Island Brain Health Collaboratory. The statewide initiative aims to speed Alzheimer's and neurological disease research, clinical implementation and workforce development, and to attract industry investment. The hub will connect Cognito with academic, healthcare and public-sector partners in the state, and the collaboratory will evaluate and deploy the Spectris platform. It is Cognito's third such collaboratory, following ones with West Virginia University's Rockefeller Neuroscience Institute and Ochsner Health. No funding amount was disclosed.
Why it matters
It shows Cognito building regional research and care networks around Spectris ahead of regulatory review, a go-to-market approach unusual for a device company. The release is company-issued and sets no milestones or budget.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items โ updated daily.
Start free trial